By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel is divided on Twist Bioscience (TWST), with concerns about its persistent net losses, high valuation, and cash burn in a high-interest-rate environment, but also acknowledging its strong revenue growth, Amazon partnership, and potential gross margin improvement. The key question is whether TWST's growth can be sustained and if its valuation is justified.
Risk: Cash burn in a high-interest-rate environment and potential liquidity crisis if revenue growth stalls or competition intensifies.
Opportunity: Potential gross margin improvement if Amazon scales its partnership beyond discovery into manufacturing revenue.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Cathie Wood's exchange-traded funds (ETFs) ended June by selling $11.2 million worth of stock in synthetic DNA manufacturer Twist Bioscience (NASDAQ: TWST). On June 30, across its Ark Innovation ETF and Ark Genomic Revolution ETF, over 114,000 shares were sold. That was on the heels of more than 84,000 shares being sold previously in the month.
Hearing that so much stock is being sold can feel concerning, as shareholders may worry that Wood has found a problem with the company that they don't know about. But there could also be not-so-worrisome reasons why the Ark ETFs are selling Twist Bioscience.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Ark's ETFs are actively managed, with stakes in companies worth millions or hundreds of millions of dollars. While selling over $11 million worth of a stock sounds significant, it also needs to be taken in context of just how much Twist Ark owns.
As of July 15, the Ark Genomic Revolution ETF held more than $121 million worth of Twist, and it was that ETF's third-largest holding. In addition, the Ark Innovation ETF holds over $211 million worth of Twist.
The size of those stakes suggests Ark hasn't lost confidence in the biotech company and may just be taking gains off the table to add to new positions. As of this writing, over the last six months, Twist Bioscience stock has climbed over 120% and more than 190% on the year.
When Ark sold $11.2 million worth of Twist Bioscience on June 30, Wood's ETFs also purchased $3.9 million worth of Circle Internet Group and $3.6 million worth of SoFi Technologies. That same day, Ark Innovation ETF and Ark Genomic Revolution each bought shares of Recursion Pharmaceuticals for $2.2 million.
That would all point to Ark freeing up capital and adding to other positions without necessarily viewing anything as being wrong with Twist Bioscience.
By manufacturing synthetic DNA on silicon chips, Twist Bioscience can help reduce research costs and accelerate discoveries across industries ranging from medicine to agriculture. Offering a nod of validation to its offerings, Amazon included Twist as one of its partners in its Amazon Bio Discovery application for testing new drugs.
Its sales are picking up steam, with 13 consecutive quarters of sequential revenue growth, and sales are also expected to jump from $376.6 million in 2025 to a range of $442 million to $447 million in 2026.
The catch is that owning Twist shares is for investors who can handle high risk. The company keeps reporting net losses,and if it reports setbacks in any upcoming quarterly report, its 190% return thus far in 2026 could face a fast and sharp reversal. A Twist investment could be a smaller, speculative addition to a portfolio, but it should be based on an investor's comfort level and understanding of the company's upside and risks, not on what Ark Invest and Cathie Wood are doing.
Before you buy stock in Twist Bioscience, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Twist Bioscience wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $371,842! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,244,783!
Now, it’s worth noting Stock Advisor’s total average return is 900% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of July 19, 2026. *
Jack Delaney has positions in SoFi Technologies. The Motley Fool has positions in and recommends Amazon and Twist Bioscience. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"Wood's modest TWST sale is portfolio rebalancing after outsized gains, not a fundamental red flag, but the stock's high valuation and ongoing losses make it a high-risk speculative name regardless of Ark's moves."
Cathie Wood's $11.2M sale of TWST on June 30 (roughly 5-7% of Ark's combined ~$332M position) looks like routine rebalancing after a 190% YTD run and 120% six-month gain, especially as she rotated into Circle, SoFi, and Recursion. Twist's 13 straight quarters of sequential revenue growth, expected FY26 revenue of $442-447M (up ~18%), and Amazon Bio Discovery partnership remain intact. However, persistent net losses and a forward P/E north of 40x leave little margin for error if any clinical or commercial milestone slips. The article downplays how concentrated Ark's remaining stake still is and the liquidity risk if Wood accelerates trimming.
The strongest case against seeing this as benign portfolio management is that Cathie has repeatedly sold winners right before fundamental cracks appeared (see past genomics names); at 190% YTD, TWST may already price in flawless execution while losses persist, setting up a sharp reversal on any revenue miss or margin disappointment.
"The 190% YTD rally in TWST has decoupled from the underlying fundamentals of a company that continues to report net losses and faces significant execution risk."
Twist Bioscience (TWST) trading at a 190% YTD gain is a classic momentum trap. While the article frames Ark’s selling as routine portfolio rebalancing, the reality is that TWST remains a cash-burning entity in a high-interest-rate environment, with no clear path to GAAP profitability despite revenue growth. The valuation is stretched; trading at high forward revenue multiples, the stock is priced for perfection. When a fund manager like Wood trims a position that has become an outsized winner, it is often a signal that the risk-reward ratio has deteriorated. Investors should be wary of chasing a stock that has already priced in aggressive adoption of its silicon-based DNA synthesis technology.
If Twist’s synthetic DNA platform achieves critical mass in the biopharma R&D pipeline, the current valuation could be justified by a massive expansion in gross margins as manufacturing scales.
"A 190% YTD rally in an unprofitable biotech company is a valuation reset, not a fundamental validation—Ark's selling into strength is the real signal, regardless of what they're buying."
The article frames Ark's $11.2M sale as benign rebalancing, but that framing deserves scrutiny. TWST is up 190% YTD—classic bubble territory for unprofitable biotech. Ark still holds $332M combined, yet they're selling into strength while simultaneously buying SOFI and CIRC. The real question: is this opportunistic profit-taking before sentiment shifts, or does Wood see TWST's valuation as detached from fundamentals? The article glosses over TWST's persistent net losses and the binary risk of 'any setback' triggering a sharp reversal—that's not a feature, it's the entire risk profile. At 190% gains, the risk/reward has inverted.
If TWST's synthetic DNA platform is genuinely accelerating drug discovery (Amazon partnership validates this), then 190% gains might reflect early-stage adoption curves, not bubble excess. Ark's sale could simply be mechanical rebalancing of a position that's grown too large—not a vote of no-confidence.
"Twist Bioscience remains a high‑beta, high‑burn growth story whose upside hinges on turning revenue growth into sustained profitability, with Ark’s sale a rotation signal rather than a verdict on the business."
Ark’s $11m Twist trim on 6/30 signals portfolio rotation more than a grim Twist verdict. Twist Bioscience is a high‑beta, high‑burn growth story: 13 straight quarters of revenue growth, $376.6m 2025 revenue, and 2026 guidance $442m–$447m, plus a notable Amazon tie‑in. Yet net losses persist and cash burn remains a risk if growth stalls or competition intensifies. Missing context includes cash runway, gross margins, customer concentration, and how sustainable pharma/bioIoT demand will be. A modest miss or delay could precipitate a sharp re‑rating even as the secular tailwinds look intact.
The flip side: Ark’s sale could reflect cooling conviction and a risk of late‑cycle multiple compression if pharma adoption slows or profitability timelines slip; Twist’s ongoing losses mean a single quarterly disappointment could trigger outsized downside.
"Valuation compression plus Amazon manufacturing upside creates more margin of safety than peers acknowledge."
Claude and Gemini both treat 190% YTD as automatic bubble evidence, yet ignore that TWST's forward EV/sales has actually compressed from 18x to ~11x on the run-up as revenue accelerated 18% guided. The real unmentioned risk is Amazon partnership optionality: if it scales beyond discovery into manufacturing revenue, gross margins could jump 800bp, justifying current multiples.
"The compression of revenue multiples is irrelevant if the company's cash burn rate outpaces its ability to secure funding in a high-rate environment."
Grok, your focus on EV/sales compression is clever, but it ignores the cost of capital. Even if revenue multiples compress, TWST's cash burn is a ticking clock in a 'higher-for-longer' rate environment. Gemini and Claude are right to fear the momentum trap; when a company relies on scaling to reach profitability, any macro-driven slowdown in pharma R&D spend turns that 'optionality' into a liquidity crisis. You're valuing a future that requires a perfect capital markets environment to exist.
"TWST's cash burn is a timing problem, not a terminal one, if gross margin expansion materializes—and the Amazon partnership makes that plausible, not speculative."
Gemini's 'ticking clock' argument assumes pharma R&D spend is cyclical and rate-sensitive. But TWST's 13-quarter revenue streak suggests demand is structural, not macro-dependent. The real test: gross margins. If Amazon scales to manufacturing (Grok's point), TWST reaches profitability faster than cash burn accelerates. Gemini conflates 'unprofitable' with 'unsustainable'—they're not synonymous for high-growth biotech. The liquidity risk is real only if revenue growth stalls.
"Margin acceleration depends on the Amazon manufacturing ramp; without it, Twist risks sharper multiple compression due to persistent cash burn and potential dilution."
Gemini's ticking-clock critique misses a pivotal hinge: Twist's margin trajectory hinges on manufacturing scale from the Amazon tie-in, not just top-line growth. If scaling costs and COGS don’t beat assumptions, the cash burn persists despite revenue, and the high forward multiple will re-rate. Also, capex and potential dilution to fund that ramp—amplified by Ark's remaining stake—creates liquidity risk even if burn slows.
The panel is divided on Twist Bioscience (TWST), with concerns about its persistent net losses, high valuation, and cash burn in a high-interest-rate environment, but also acknowledging its strong revenue growth, Amazon partnership, and potential gross margin improvement. The key question is whether TWST's growth can be sustained and if its valuation is justified.
Potential gross margin improvement if Amazon scales its partnership beyond discovery into manufacturing revenue.
Cash burn in a high-interest-rate environment and potential liquidity crisis if revenue growth stalls or competition intensifies.